ATE410183T1 - Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden - Google Patents

Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden

Info

Publication number
ATE410183T1
ATE410183T1 AT99968288T AT99968288T ATE410183T1 AT E410183 T1 ATE410183 T1 AT E410183T1 AT 99968288 T AT99968288 T AT 99968288T AT 99968288 T AT99968288 T AT 99968288T AT E410183 T1 ATE410183 T1 AT E410183T1
Authority
AT
Austria
Prior art keywords
related methods
adjuvant compositions
based adjuvant
adjuvant
animal
Prior art date
Application number
AT99968288T
Other languages
English (en)
Inventor
John Walker
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Application granted granted Critical
Publication of ATE410183T1 publication Critical patent/ATE410183T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
AT99968288T 1999-01-08 1999-12-24 Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden ATE410183T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP8073A AUPP807399A0 (en) 1999-01-08 1999-01-08 Improved immunogenic lhrh composition and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE410183T1 true ATE410183T1 (de) 2008-10-15

Family

ID=3812278

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968288T ATE410183T1 (de) 1999-01-08 1999-12-24 Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden

Country Status (15)

Country Link
US (2) US9579379B1 (de)
EP (2) EP1140165B1 (de)
JP (2) JP4949555B2 (de)
AT (1) ATE410183T1 (de)
AU (2) AUPP807399A0 (de)
CA (2) CA2660344A1 (de)
CY (1) CY1108693T1 (de)
DE (1) DE69939706D1 (de)
DK (1) DK1140165T3 (de)
ES (1) ES2317708T3 (de)
NZ (1) NZ512011A (de)
PT (1) PT1140165E (de)
TW (1) TW533079B (de)
WO (1) WO2000041720A1 (de)
ZA (1) ZA200105543B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE464907T1 (de) 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
GB0008877D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
GB0008879D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
KR100958505B1 (ko) * 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
RU2007143992A (ru) * 2005-06-01 2009-07-20 Пфайзер Продактс Инк. (Us) Вакцинные композиции и способы лечения недержания мочи
WO2008110912A1 (en) * 2007-03-14 2008-09-18 Pfizer Inc. Fertility regulation in horses
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
IN2012DN00446A (de) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
PE20121544A1 (es) 2009-09-03 2012-12-02 Pfizer Vaccines Llc Vacuna de pcsk9
NZ629256A (en) 2009-12-22 2016-02-26 Celldex Therapeutics Inc Vaccine compositions
EP2575868A1 (de) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
UA114086C2 (xx) 2011-05-13 2017-04-25 Імуногенна композиція глікопротеїну g вірусу hendra і/або nipah
SG11201400916XA (en) 2011-08-22 2014-06-27 Cangene Corp Clostridium difficile antibodies
EP2659907A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
EP2659906A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
SG11201510740YA (en) 2013-09-17 2016-01-28 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
RU2730011C2 (ru) 2013-09-19 2020-08-14 Зоэтис Сервисиз Ллс Адъюванты на масляной основе
EP3082856A1 (de) 2013-12-16 2016-10-26 Zoetis Services LLC Immunogene hendra- und nipah-virus-g-glycoprotein-zusammensetzungen
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3206112A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
KR20170041167A (ko) 2014-02-19 2017-04-14 조디 베리 마르부르크 단클론성 항체
EP3662928A1 (de) 2014-04-10 2020-06-10 OBI Pharma Inc. Antikörper, die an tumor assoziierte kohlehydrat-antigene binden, pharmazeutische zusammensetzungen und deren anwendung
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
FI3244920T3 (fi) * 2015-01-16 2023-08-04 Zoetis Services Llc Suu- ja sorkkatautirokote
EP3302536A1 (de) 2015-06-03 2018-04-11 Affiris AG Il-23-p19-impfstoffe
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
EP3325008B1 (de) 2015-07-21 2025-09-10 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharid-antigenen, kits damit und verwendungen davon
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
KR20250007054A (ko) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI780045B (zh) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
AU2017252128B2 (en) 2016-04-22 2024-06-06 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
TWI853822B (zh) 2018-06-27 2024-09-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020055503A1 (en) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3914708A1 (de) 2019-01-24 2021-12-01 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN112516325B (zh) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用
CA3159573A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021223184C1 (en) 2020-02-23 2025-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
CN113967252B (zh) * 2020-07-24 2024-03-26 洛阳赛威生物科技有限公司 一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021368151B2 (en) 2020-10-27 2024-09-05 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021373358B2 (en) 2020-11-04 2026-01-08 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US20240299510A1 (en) 2020-12-31 2024-09-12 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
CN118695869A (zh) 2022-02-14 2024-09-24 佐治亚大学研究基金会股份有限公司 泛-肺病毒疫苗组合物及其使用方法
CN121358749A (zh) * 2023-07-07 2026-01-16 欧鲁菲诺动物保健有限责任公司 用于哺乳动物免疫去势的修饰的GnRH肽及其缀合物、制备方法、组合物和试剂盒
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1924304C3 (de) * 1969-05-13 1980-07-17 Bayer Ag, 5090 Leverkusen Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren
DE3411224A1 (de) 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
EP0231039B1 (de) * 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Verfahren zur Herstellung immunologischer Komplexe und diese enthaltende pharmazeutische Zusammensetzung
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
AU602187B2 (en) * 1987-01-14 1990-10-04 Commonwealth Scientific And Industrial Research Organisation Anti-reproductive hormone
GB8707398D0 (en) * 1987-03-27 1987-04-29 Coopers Animal Health Biologically active molecules
US4892830A (en) * 1987-04-02 1990-01-09 Baylor College Of Medicine Environmentally controlled in vitro incubator
GB2228262B (en) 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
AU5186090A (en) 1989-02-23 1990-09-26 Colorado State University Research Foundation Gnrh analogs for destroying gonadotrophs
US5403586A (en) * 1989-08-25 1995-04-04 Biotechnology Australia Ptl Ltd. LHRH-TraTp fusion proteins
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
US5324512A (en) 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AU7468196A (en) 1995-10-27 1997-05-15 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US6013770A (en) 1997-07-21 2000-01-11 Washington State University Chimeric contraceptive vaccines
AUPP060097A0 (en) * 1997-11-28 1998-01-08 Commonwealth Scientific And Industrial Research Organisation Adjuvant system for enhanced response

Also Published As

Publication number Publication date
CY1108693T1 (el) 2012-05-23
NZ512011A (en) 2002-12-20
US9149520B2 (en) 2015-10-06
ZA200105543B (en) 2003-01-22
JP2002534480A (ja) 2002-10-15
EP1946773A3 (de) 2008-07-30
WO2000041720A8 (en) 2000-11-09
CA2359111A1 (en) 2000-07-20
US20120251566A1 (en) 2012-10-04
AU2526300A (en) 2000-08-01
EP1140165A1 (de) 2001-10-10
DK1140165T3 (da) 2009-02-16
US9579379B1 (en) 2017-02-28
TW533079B (en) 2003-05-21
CA2660344A1 (en) 2000-07-20
JP2012072157A (ja) 2012-04-12
EP1946773A2 (de) 2008-07-23
EP1140165A4 (de) 2005-01-05
JP4949555B2 (ja) 2012-06-13
ES2317708T3 (es) 2009-04-16
PT1140165E (pt) 2009-01-13
AU758133B2 (en) 2003-03-13
WO2000041720A1 (en) 2000-07-20
DE69939706D1 (de) 2008-11-20
EP1140165B1 (de) 2008-10-08
CA2359111C (en) 2014-02-18
AUPP807399A0 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
ATE410183T1 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
ATE229978T1 (de) Helicobacter proteine und impstoffe
AU4324996A (en) Novel cyclodextrin-derivatives and methods for the preparation thereof
EP1326633A4 (de) Zusammensetzung mit immunogenen mikroteilchen
DK0764029T4 (da) Proteinadjuvanser
DK55891D0 (da) Matrix med immunomodulerende virkning
ZA936629B (en) Potentiation of immunogenic response
DK0957935T3 (da) Chlamydia-vacciner og immunogene præparater indeholdende et ydre membran-antigen samt fremgangsmåde til fremstilling deraf
NO991524L (no) Vaksiner
FR2781159B1 (fr) Vaccin circovirus et parvovirus porcin
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
CA2352563A1 (en) Method to produce inactivated w/o emulsion adjuvanted vaccines
FI972054A0 (fi) Immunogeenisiä koostumuksia
NL980007I1 (nl) Acellulair vaccin.
BR9815404A (pt) Composição adjuvante para estimular uma eficiente resposta imunológica a uma substância antigênica, vacina para administração a um animal, processo para estimular uma resposta imunológica eficaz em um animal a uma substância antigênica, e, uso da composição adjuvante.
AR010568A1 (es) Polipeptido, composicion de vacuna, uso del polipeptido en la fabricacion de una composicion, y metodo para producir en un mamifero una respuestainmuno-protectora contra la infeccion de helicobacter pylori
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
NL300073I1 (nl) Vaccin.
DK0485463T3 (da) Svækket hundeparvovirus (CPV), vaccine omfattende CPV og fremgangsmåde til forebyggelse af CPV-infektion i hunde
SE9600646D0 (sv) Vaccin
MX9700215A (es) Proteinas y vacunas de helicobacter.
MX9710523A (es) Vacunas contra hepatitis c.
MX9708226A (es) Vacunas que contienen una saponina y un esterol.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140165

Country of ref document: EP